PUBLICATIONS
2025
TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.
Pottier A, Park S, Lee Y, Liccardo F, Yang H, Park J, Lorant A, Schnekenburger M, Brusa D, Li V, Valente S, Mai A, Skuli SJ, Carroll M, Boettcher S, Sarry JE, Cerella C, Morceau F, Diederich M. Cancer Lett. 2025 Sep 1;633:218011. doi: 10.1016/j.canlet.2025.218011.
Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M. Leukemia. 2025 Sep;39(9):2087-2098.
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M. Blood. 2025 Nov 20;146(21):2574-2588.
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect.
Klemm N, Schimmer RR, Konrad NK, Thelen F, Fullin J, Topçu E, Koch C, Treacy M, Leventhal MJ, Bühler MM, Lysenko V, Theocharides APA, Kurppa KJ, Balabanov S, Baubec T, Krivtsov AV, Miller PG, Armstrong SA, Ebert BL, Manz MG, Nombela-Arrieta C, Boettcher S. Cancer Res. 2025 Jun 2;85(11):1978-1996.
IN THE SPOTLIGHT
Targeted Degradation of Mutant p53 Reverses the Pro-oncogenic Dominant-Negative Effect.
Jovanka Gencel-Augusto & Guillermina Lozano. Cancer Res. 2025 Jun 2;85(11):1955-1956.
Prolonged persistence of mutagenic DNA lesions in somatic cells.
Spencer Chapman M, Mitchell E, Yoshida K, Williams N, Fabre MA, Ranzoni AM, Robinson PS, Kregar LD, Wilk M, Boettcher S, Mahbubani K, Saeb Parsy K, Gowers KHC, Janes SM, Ng SWK, Hoare M, Green AR, Vassiliou GS, Cvejic A, Manz MG, Laurenti E, Martincorena I, Stratton MR, Nangalia J, Coorens THH, Campbell PJ. Nature. 2025 Feb;638(8051):729-738.
2024
Clonal dynamics after allogeneic haematopoietic cell transplantation.
Spencer Chapman M, Wilk CM, Boettcher S, Mitchell E, Dawson K, Williams N, Müller J, Kovtonyuk L, Jung H, Caiado F, Roberts K, O'Neill L, Kent DG, Green AR, Nangalia J, Manz MG, Campbell PJ. Nature. 2024 Nov;635(8040):926-934.
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S. EMBO Mol Med. 2024 Mar;16(3):445-474.
2023
Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.
Wilk CM, Cathomas F, Török O, Le Berichel J, Park MD, Bigenwald C, Heaton GR, Hamon P, Troncoso L, Scull BP, Dangoor D, Silvin A, Fleischmann R, Belabed M, Lin H, Merad Taouli E, Boettcher S, Li L, Aubry A, Manz MG, Kofler JK, Yue Z, Lira SA, Ginhoux F, Crary JF, McClain KL, Picarsic JL, Russo SJ, Allen CE, Merad M. Immunity. 2023 Dec 12;56(12):2790-2802.e6.
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Sci Adv. 2023 Dec;9(48):eadh1436.
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.
Miller PG, Sperling AS, Mayerhofer C, McConkey ME, Ellegast JM, Da Silva C, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter I, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL. Blood. 2023 Dec 14;142(24):2079-2091.
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.
Marion W, Koppe T, Chen CC, Wang D, Frenis K, Fierstein S, Sensharma P, Aumais O, Peters M, Ruiz-Torres S, Chihanga T, Boettcher S, Shimamura A, Bauer DE, Schlaeger T, Wells SI, Ebert BL, Starczynowski D, da Rocha EL, Rowe RG. Leukemia. 2023 Aug;37(8):1698-1708.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Blood. 2023 Sep 21;142(12):1056-1070.
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Blood Cancer J. 2023 Apr 24;13(1):57.
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Blood Cancer J. 2023 Apr 13;13(1):53.
Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.
Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Blood. 2023 Feb 23;141(8):886-903.
2022
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Leukemia. 2022 Nov;36(11):2729-2733.
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells.
Sellar RS, Sperling AS, Słabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, Dutta RK, Boettcher S, Lin AE, Sandoval B, Quevedo Barrios VA, Kovalcik V, Koeppel J, Henderson EK, Fink EC, Yang L, Chan A, Pokharel SP, Bergstrom EJ, Burt R, Udeshi ND, Carr SA, Fischer ES, Chen CW, Ebert BL. J Clin Invest. 2022 Aug 15;132(16):e153514.
TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.
Schimmer RR, Kovtonyuk LV, Klemm N, Fullin J, Stolz SM, Mueller J, Caiado F, Kurppa KJ, Ebert BL, Manz MG, Boettcher S. Blood Adv. 2022 Jun 14;6(11):3201-3206.
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Blood Cancer J. 2022 Jan 11;12(1):5.
CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesis.
Gerosa RC, Boettcher S, Kovtonyuk LV, Hausmann A, Hardt WD, Hidalgo J, Nombela-Arrieta C, Manz MG. Blood Adv. 2021 Dec 14;5(23):5002-5015.
IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice.
Kovtonyuk LV, Caiado F, Garcia-Martin S, Manz EM, Helbling P, Takizawa H, Boettcher S, Al-Shahrour F, Nombela-Arrieta C, Slack E, Manz MG. Blood. 2022 Jan 6;139(1):44-58.
2021
Clonal hematopoiesis in hematopoietic stem cell transplantation.
Wilk CM, Manz MG, Boettcher S. Curr Opin Hematol. 2021 Mar 1;28(2):94-100.
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
Kennedy AL, Myers KC, Bowman J, Gibson CJ, Camarda ND, Furutani E, Muscato GM, Klein RH, Ballotti K, Liu S, Harris CE, Galvin A, Malsch M, Dale D, Gansner JM, Nakano TA, Bertuch A, Vlachos A, Lipton JM, Castillo P, Connelly J, Churpek J, Edwards JR, Hijiya N, Ho RH, Hofmann I, Huang JN, Keel S, Lamble A, Lau BW, Norkin M, Stieglitz E, Stock W, Walkovich K, Boettcher S, Brendel C, Fleming MD, Davies SM, Weller EA, Bahl C, Carter SL, Shimamura A, Lindsley RC. Nat Commun. 2021 Feb 26;12(1):1334.
2020
An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation.
Marion W, Boettcher S, Ruiz-Torres S, Lummertz da Rocha E, Lundin V, Morris V, Chou S, Zhao AM, Kubaczka C, Aumais O, Zhang Y, Shimamura A, Schlaeger TM, North TE, Ebert BL, Wells SI, Daley GQ, Rowe RG. Blood Adv. 2020 Oct 13;4(19):4679-4692.
Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID-19.
Hameister E, Stolz SM, Fuhrer Y, Thienemann F, Schaer DJ, Nemeth J, Schuepbach RA, Goede J, Reinhart S, Schmidt A, Kahraman A, Schmid M, Moch H, Zoche M, Manz MG, Balabanov S, Boettcher S. Hemasphere. 2020 Aug 10;4(4):e453. doi: 10.1097/HS9.0000000000000453.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. Blood. 2020 Jul 30:blood.2020006158.
Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation.
Boettcher S, Wilk CM, Singer J, Beier F, Burcklen E, Beisel C, Ventura Ferreira MS, Gourri E, Gassner C, Frey BM, Schanz U, Skoda RC, Ebert BL, Brümmendorf TH, Beerenwinkel N, Manz MG. Blood. 2020 Mar 16. pii: blood.2019003079. doi: 10.1182/blood.2019003079.
COMMENT
Home and away: clonal hematopoiesis in sibling transplants.
Margarete A Fabre & George S Vassiliou. Blood. 2020 Apr 30;135(18):1511-1512.
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA. Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006.
2019
Global Transcriptomic Profiling of the Bone Marrow Stromal Microenvironment during Postnatal Development, Aging, and Inflammation.
Helbling PM, Piñeiro-Yáñez E, Gerosa R, Boettcher S, Al-Shahrour F, Manz MG, Nombela-Arrieta C. Cell Rep. 2019 Dec 3;29(10):3313-3330.
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. Science. 2019 Aug 9;365(6453):599-604.
PERSPECTIVE
How to loose tumor suppression.
David P. Lane. Science. 2019 Aug 9;365(6453):539-540.
Clonal Hematopoiesis of Indeterminate Potential.
Boettcher S, Ebert BL. J Clin Oncol. 2019 Feb 10;37(5):419-422.
2017
Regulation of Inflammation- and Infection-Driven Hematopoiesis.
Boettcher S, Manz MG. Trends Immunol. 2017 May;38(5):345-357.
2016
Ziegler P, Boettcher S, Takizawa H, Manz MG, Brümmendorf TH. Ann Hematol. 2016 Jan;95(2):173-8.
Sensing and translation of pathogen signals into demand-adapted myelopoiesis.
Boettcher S, Manz MG. Curr Opin Hematol. 2016 Jan;23(1):5-10.
2014
DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis.
Sendoel A, Maida S, Zheng X, Teo Y, Stergiou L, Rossi CA, Subasic D, Pinto SM, Kinchen JM, Shi M, Boettcher S, Meyer JN, Manz MG, Bano D, Hengartner MO. Nat Cell Biol. 2014 Aug;16(8):812-20.
Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis.
Boettcher S, Gerosa RC, Radpour R, Bauer J, Ampenberger F, Heikenwalder M, Kopf M, Manz MG. Blood. 2014 Aug 28;124(9):1393-403.
A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformation.
Sievert H, Pällmann N, Miller KK, Hermans-Borgmeyer I, Venz S, Sendoel A, Preukschas M, Schweizer M, Boettcher S, Janiesch PC, Streichert T, Walther R, Hengartner MO, Manz MG, Brümmendorf TH, Bokemeyer C, Braig M, Hauber J, Duncan KE, Balabanov S. Dis Model Mech. 2014 Aug;7(8):963-76.
Emergency granulopoiesis.
Manz MG, Boettcher S. Nat Rev Immunol. 2014 May;14(5):302-14.
2012
Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.
Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Cancer Cell. 2012 Jul 10;22(1):91-105.
Cutting edge: LPS-induced emergency myelopoiesis depends on TLR4-expressing nonhematopoietic cells.
Boettcher S, Ziegler P, Schmid MA, Takizawa H, van Rooijen N, Kopf M, Heikenwalder M, Manz MG. J Immunol. 2012 Jun 15;188(12):5824-8.
Demand-adapted regulation of early hematopoiesis in infection and inflammation.
Takizawa H, Boettcher S, Manz MG. Blood. 2012 Mar 29;119(13):2991-3002.
2011
Acquired coagulopathy caused by intoxication with the superwarfarin-type anticoagulant rodenticide flocoumafen.
Boettcher S, Wacker A, Moerike K, Kopp HG, Jaschonek K, Grobosch T, Kanz L, Salih HR. Eur J Haematol. 2011 Feb;86(2):173-5.